EN | UA
EN | UA

Help Support

Back

Real-world study determines efficacy of Omalizumab and Hydroxychloroquine in urticaria

Chronic spontaneous urticaria Chronic spontaneous urticaria
Chronic spontaneous urticaria Chronic spontaneous urticaria

What's new?

Owing to Hydroxychloroquine's favorable safety profile, it may be considered as an adjunct therapy for refractory chronic spontaneous urticaria.

In a real-world trial, although the monoclonal antibody Omalizumab was better, Hydroxychloroquine attained a full response in two-thirds of treated chronic spontaneous urticaria (CSU) patients. Najeeb Khan et al. sought to evaluate the efficacy of several add-on therapy options for CSU.

In 264 people with CSU who had not been successfully treated for ≥six weeks with optimal dosages of 2nd generation histamine-1 blockers, a retrospective chart review was conducted. The two drugs that were most often given as add-on therapy were Omalizumab and Hydroxychloroquine, permitting comparisons of their clinical results. Patient satisfaction with the therapy and absent or rare urticaria were all signs of a complete response. Decreased hives were a partial response, but a 2nd add-on medication was still necessary.

The sustained response was defined as a complete response following an add-on therapy for ≥ one year. Compared to Hydroxychloroquine, Omalizumab add-on therapy dramatically increased the probability of a complete response. Notably, 111 out of 134 subjects (82%) receiving Omalizumab and 73 out of 111 patients (66%) receiving Hydroxychloroquine as the initial add-on treatment experienced a complete sustained response at the 1-year.

Add-on therapies were less effective for patients with thyroid disease (45% vs. 63% responders). Patients (n = 45) who had only partially responded to the initial add-on therapies later had complete responses to Omalizumab (65%) and Hydroxychloroquine (62%) respectively. Due to Hydroxychloroquine's high responder rate and reduced cost, it appears to be an acceptable alternative to Omalizumab for CSU management.

Source:

The Journal of Allergy and Clinical Immunology: In Practice

Article:

Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: a real-world study

Authors:

Najeeb Khan et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: